about
Poverty and racial disparities in kidney disease: the REGARDS study.Predictors of delayed transition from central venous catheter use to permanent vascular access among ESRD patients.Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.Improving the care of ESRD patients: a success story.Geographic concentration of poverty and arteriovenous fistula use among ESRD patientsAlbuminuria and racial disparities in the risk for ESRD.High one year mortality in adults with sickle cell disease and end-stage renal disease.Association of family history of ESRD, prevalent albuminuria, and reduced GFR with incident ESRD.Treatment center and geographic variability in pre-ESRD care associate with increased mortality.Predictors of central venous catheter use at the initiation of hemodialysis.Chronic kidney disease is often unrecognized among patients with coronary heart disease: The REGARDS Cohort Study.Epidemiology, geography and chronic kidney disease.Geographic disparities in patient travel for dialysis in the United States.Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis.Disparity in outcomes for adult Native American hemodialysis patients? Findings from the ESRD Clinical Performance Measures Project, 1996 to 1999.Diabetes is the strongest risk factor for lower-extremity amputation in new hemodialysis patients.Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction.Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction.Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease.Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: process, outcomes, and implications.Survival advantage for adult Hispanic hemodialysis patients? Findings from the end-stage renal disease clinical performance measures project.Survival advantage of black patients with kidney disease after acute myocardial infarction.
P50
Q34038090-EBB24A58-2255-4E2F-816A-E6ADFD31531FQ34089893-CCF51D4A-BAB0-43E7-A2C1-468CB87F375DQ34238467-46399855-3440-4ED6-B93D-F767A0C632D8Q34327810-0006835B-54F8-4039-A030-02F672B90E20Q34455416-81B650DD-E030-4AE2-98E9-0B9A597B26BAQ35210216-917CD190-5080-4D7C-8370-5A4D4E9CD321Q36035191-B80A6587-F5C3-44D2-8B95-839B3E016C76Q37051969-73B1EC96-2052-491A-B516-6C7BFFE82252Q37181980-22550F7E-07D1-4CB3-A36C-01CC4F84E498Q37310035-63F87BF2-5DBD-41A8-8502-45A1CB64FDD0Q37449537-974528A1-6CDD-43AB-870C-BF588194C73EQ37990377-FF77008B-C128-4640-B46A-E2A8FC021C8BQ40141167-718B233A-20D3-42EF-9850-A6E1B167110EQ44237532-AC7482E4-1ABC-4587-A8C0-FC04796AE064Q44845996-CC9C6C57-520E-45E6-ADD2-9A64C823E438Q45034119-9836C6C9-B998-4E4B-ABC0-16A2B2F72F71Q46603378-54897AD6-856D-4A61-A969-FCA410972EA9Q46686025-F1B1B2E3-19B8-409B-B8EA-845709AD84C5Q46720242-220AC565-B88A-4634-AAD2-187FD98F6A68Q47593100-FB87898D-044D-456C-8FAF-D02DEA5260D7Q50194955-93DD26C7-7227-4DCB-B7D4-BE70646AD63BQ51741914-79B97978-DD6C-45CB-8516-40A07F474F12
P50
description
Amerikaans onderzoeker (1947-2017)
@nl
name
William M. McClellan
@ast
William M. McClellan
@ca
William M. McClellan
@en
William M. McClellan
@es
William M. McClellan
@fr
William M. McClellan
@nl
William M. McClellan
@sl
type
label
William M. McClellan
@ast
William M. McClellan
@ca
William M. McClellan
@en
William M. McClellan
@es
William M. McClellan
@fr
William M. McClellan
@nl
William M. McClellan
@sl
prefLabel
William M. McClellan
@ast
William M. McClellan
@ca
William M. McClellan
@en
William M. McClellan
@es
William M. McClellan
@fr
William M. McClellan
@nl
William M. McClellan
@sl
P106
P21
P31
P569
1947-03-30T00:00:00Z
P570
2017-03-09T00:00:00Z